OR WAIT null SECS
Novo Nordisk broke ground on a facility in Clayton, NC, to manufacture APIs for GLP-1 and insulin medicines.
Novo Nordisk broke ground on its new $1.8 billion diabetes medicine production facility in Clayton, NC, the company announced in a March 28, 2016 press release. The facility will produce APIs for a range of Novo Nordisk's current and future GLP-1 and insulin medicines. The Clayton facility is expected to be fully operational by 2020.
The new facility will measure 833,000 ft2 and have a footprint of 417,639 ft2. This expansion is expected to create close to 700 new jobs, as well as have up to 2500 people working on the project at peak construction.
"As the prevalence of diabetes has grown in the US, so too has the demand for effective treatments," said Lars Rebien Sørensen, president and CEO of Novo Nordisk. "It gives me great pride to break ground on our new facility site in Clayton where we have an existing, strong organization. This site will play a vital role in enabling us to meet the needs of people living with diabetes in the US for years to come."
The new site is situated adjacent to Novo Nordisk's 457,000-ft2 Clayton, NC facility. Expanded several times since it was inaugurated in 1996, Novo Nordisk's current plant in Clayton, NC is one of the company's strategic production sites responsible for formulation, filling, and packaging of diabetes medicines. The plant also assembles and packages the company's FlexPen and FlexTouch prefilled insulin devices for the US market.
Once the new site becomes operational, the diabetes API production organization in Clayton will be named DAPI-US (Diabetes Active Pharmaceutical Ingredients-US). It will be part of the Danish diabetes API production organization in Kalundborg, which will be named DAPI-Denmark. The company is also investing in its manufacturing facilities in Denmark.
Source: Novo Nordisk